CTIS2023-504786-23-00进行中（未招募）1 期
A Phase 1/2 Dose-escalation Study Evaluating the Safety, Tolerability, and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy - VX21-522-001
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- •Subject will sign and date an informed consent form., Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures., Subjects (male and female) between the ages of 18 and 65 years, inclusive., Body mass index (BMI) of <30.0 kg/m2 and a total body weight >50 kg., Nonsmoker or ex-smoker for at least 3 months before screening with current nonsmoking status confirmed by urine or blood cotinine at screening., CFTR mutations on both alleles that are not responsive to CFTR modulator therapy., Stable CF disease, as judged by the investigator, and FEV1 value, percent of predicted mean for age, sex, and height =40%, Willing to remain on a stable CF treatment regimen through completion of study participation.
排除标准
- •History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drugs to the subject., Lung infection with organisms associated with a more rapid decline in pulmonary status., Alcohol or drug abuse in the past year, including, but not limited to, abuse of cannabis, cocaine, and opiates., Any clinically significant laboratory abnormalities that would interfere with the study assessments or pose an undue risk for the subject., Arterial oxygen saturation on room air <94% at screening or use of supplemental oxygen within 28 days before the first dose of study drug., Any of the following abnormal laboratory values at screening: Hemoglobin <10 g/dL, Total bilirubin =2 × ULN, AST, ALT, GGT, or ALP =3 × ULN, Abnormal renal function, defined as glomerular filtration rate =50 mL/min/1.73 m2, For female subjects: Pregnant or breast-feeding. Females of childbearing potential must have a negative pregnancy test at the Screening Visit and before the first dose of study drug. For male subjects: Male subjects with a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 180 days after the last dose of study drug., Standard 12 lead ECG median of triplicate demonstrating QTcF >450 msec at screening., An acute upper or lower respiratory tract infection, PEx, or changes in therapy for pulmonary disease within 28 days before the first dose of study drug.
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/2 Study with Ascending Dose in order to Evaluate the Safety and Effects on Progranulin Levels of investigational product under code LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN)MedDRA version: 21.1Level: PTClassification code: 10068968Term: Frontotemporal dementia Class: 100000004852CTIS2022-502942-29-01Prevail Therapeutics Inc.35
进行中（未招募）
1 期
A Phase 1/2 Study with Ascending Dose in order to Evaluate the Safety and Effects on Progranulin Levels of investigational product under code LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN)MedDRA version: 21.1Level: PTClassification code 10068968Term: Frontotemporal dementiaSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-003159-12-BEPrevail Therapeutics, a wholly-owned subsidiary of Eli Lilly and Company35
进行中（未招募）
1 期
A study to investigate the safety, tolerability and efficacy of PCI/Gemcitabine treatment followed by combination chemotherapy in patients with cholangiocarcinomasInoperable advanced cholangiocarcinomasMedDRA version: 20.0Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 100000054936EUCTR2012-002888-10-GBPCI Biotech AS68
进行中（未招募）
1 期
A study to investigate the safety, tolerability and efficacy of PCI/Gemcitabine treatment followed by combination chemotherapy in patients with cholangiocarcinomasInoperable advanced cholangiocarcinomasMedDRA version: 20.0 Level: LLT Classification code 10008594 Term: Cholangiocarcinoma non-resectable System Organ Class: 100000004864EUCTR2012-002888-10-FRPCI Biotech AS61
进行中（未招募）
1 期
A study to investigate the safety, tolerability and efficacy of PCI/Gemcitabine treatment followed by combination chemotherapy in patients with cholangiocarcinomasInoperable advanced cholangiocarcinomasMedDRA version: 19.0 Level: LLT Classification code 10008594 Term: Cholangiocarcinoma non-resectable System Organ Class: 100000004864EUCTR2012-002888-10-LTPCI Biotech AS61